Next » | All Messages |  HDVY Message Board Home | recommend post |  Ignore Poster

HDVY News Health Discovery Corporation Receives Pioneering U.S. Patent for Its Renowned RFE-SVM Technology

SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”)(OTCBB: HDVY) today announced the issuance of its pioneering U.S. patent covering the well-established and widely-used recursive feature elimination (“RFE”) method for support vector machines (“SVM”), a major addition to its intellectual property portfolio. RFE is a mathematical selection/filtering process that successively eliminates the least important of many data features, then ranks each of the most significant of the relatively few features remaining for simultaneous use in classifying the data using SVMs. The most significant benefit is an increase in the accuracy and usefulness of the classification results, particularly when analyzing voluminous data. A 2002 Machine Learning article by the inventors and others that initially described RFE-SVMs has been repeatedly cited by hundreds of researchers worldwide. Internet search engines provide over a thousand additional references demonstrating the importance and widespread acceptance of this significant enhancement to SVM methodologies.

Isabelle Guyon, Ph.D., world famous co-inventor of SVM technology, lead inventor of the RFE, and a member of HDC's Scientific Team, noted: "Because of its simplicity and efficiency, RFE-SVM has quickly become a reference method for SVM-based feature selection. The technology offers the power of multi-variate feature selection with little additional computational expense compared to a traditional SVM. In fact, HDC successfully used the RFE-SVM to discover its unique biomarkers for the diagnosis of colon cancer, clinically significant prostate cancer and BPH (enlarged prostate).”

Hong Zhang, Ph.D., HDC’s Senior Vice President for Computational Medicine commented: “RFE is a great revolutionary idea in its own right, not just an evolutionary step under SVM.”

"This very important RFE-SVM patent is truly seminal in character and could be a huge factor in HDC's future,” said Stephen D. Barnhill, M.D., HDC’s Chairman and CEO and a co-author of the original RFE article. “The RFE-SVM tool has become a methodology of choice for biological data analysis because of its efficient and accurate classification capabilities with very large data volumes. We believe this tool is particularly well-suited to the analytical needs of the genomics and proteomics markets which now exceed $5 billion and are growing at 25-35% annual rates. Interestingly, it is now also starting to find acceptance in other areas such as text and image recognition. The widespread use of RFE-SVMs in academia and the biotech arena affords HDC superb opportunities to establish mutually beneficial relationships with the many organizations that have found our proprietary technology so helpful. We believe this development will also add to HDC's growing reputation in pattern recognition using SVMs in both the medical and non-medical fields.”

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery^sm. The Company's SVM and other pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.